×
About 14,470 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,095 results

Cutaneous Eruption in an Immunocompromised Patient
https://www.mdedge.com/dermatology/article/258385/infectious-diseases/cutaneous-eruption-immunocompromised-patient
Hesham Alshaikh, MD, Ahmad Aleisa, MD et. al.

Oct 4th, 2022 - The Diagnosis: Secondary Syphilis Histopathology revealed a lichenoid interface dermatitis with psoriasiform hyperplasia (Figure 1A). A single spirochete was identified using immunohistochemical staining (Figure 1B).

Annular plaque over the scalp with patchy alopecia.
https://doi.org/10.1111/ijd.16442
International Journal of Dermatology; Sharma A, Vinay K et. al.

Oct 3rd, 2022 - Annular plaque over the scalp with patchy alopecia.|2022|Sharma A,Vinay K,Chatterjee D,Narang T,Dogra S,|

Eyebrow and Eyelash Alopecia: A Clinical Review.
https://doi.org/10.1007/s40257-022-00729-5
American Journal of Clinical Dermatology; Nguyen B, Hu JK et. al.

Oct 3rd, 2022 - Madarosis is characterized by either complete or partial loss of eyebrow or eyelash hair. Etiologies for madarosis are varied, and accurate diagnosis is the first step in clinical management. Many studies have described findings related to specifi...

Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis ...
https://doi.org/10.1111/1346-8138.16595
The Journal of Dermatology; Chromy D, Bartosik T et. al.

Oct 1st, 2022 - Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a typical type-2 inflammation involving T-helper type-2 cells and impairing quality of life due to nasal obstruction, discharge and reduced sense of smell. Recently, the anti-IL4Rα antibody d...

Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Ar...
https://doi.org/10.1111/dth.15871
Dermatologic Therapy; Husein-ElAhmed H, Abdulla N et. al.

Oct 1st, 2022 - Tofacitinib is a pan-janus kinase inhibitor (JAK) which has been tested off-label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real-life setting is still poor. We evaluated long-term efficacy and safety of to...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  375 results see all →

Clinicaltrials.gov  440 results

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Sep 30th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03898479

Sep 30th, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

Sep 29th, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2)
https://clinicaltrials.gov/ct2/show/NCT04797650

Sep 29th, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that s...

Natural History and Pathogenesis of Alopecia in Children and Adults
https://clinicaltrials.gov/ct2/show/NCT05502796

Sep 29th, 2022 - Study Description: This is a study to detail the characteristics (genetic, immunologic, biological and demographic) of individuals who present in childhood and adulthood with alopecia and how alopecia impacts skin and systemic symptoms. Objectives...

see more →

News  863 results

Cutaneous Eruption in an Immunocompromised Patient
https://www.mdedge.com/dermatology/article/258385/infectious-diseases/cutaneous-eruption-immunocompromised-patient
Hesham Alshaikh, MD, Ahmad Aleisa, MD et. al.

Oct 4th, 2022 - The Diagnosis: Secondary Syphilis Histopathology revealed a lichenoid interface dermatitis with psoriasiform hyperplasia (Figure 1A). A single spirochete was identified using immunohistochemical staining (Figure 1B).

FDA Approves Futibatinib (Lytgobi) for Certain Biliary Tract Cancers
https://www.medscape.com/viewarticle/981752

Oct 3rd, 2022 - The US Food and Drug Administration (FDA) has granted an accelerated approval for a new drug, futibatinib (Lytgobi), to be used for patients with a certain type of biliary tract cancer. Futibatinib was granted priority review and breakthrough desi...

BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema
https://www.medscape.com/viewarticle/981709

Sep 30th, 2022 - The oral Janus kinase (JAK) inhibitor baricitinib appears to improve symptoms of atopic dermatitis (AD) in children aged 2 years and up, as indicated by data from the phase 3 BREEZE-AD-PEDS trial. After 16 weeks of treatment, the primary endpoint ...

Alopecia Areata: Positive Results Reported for Two Investigational JAK Inhibitors
https://www.medscape.com/viewarticle/981622

Sep 29th, 2022 - Treatment with deuruxolitinib and ritlecitinib, two investigational Janus kinase (JAK) inhibitors, resulted in substantial regrowth of scalp hair for patients with alopecia areata (AA) in separate studies reported at the European Academy of Dermat...

FDA Fast Tracks Approval of Novel Therapy for Rare Neurologic Disorder
https://www.medscape.com/viewarticle/981025

Sep 19th, 2022 - The US Food and Drug Administration (FDA) has granted accelerated approval to the novel gene therapy elivaldogene autotemcel (Skysona, bluebird bio) for the treatment of cerebral adrenoleukodystrophy (CALD). The therapy "is indicated to slow the p...

see more →

Patient Education  12 results see all →